BBLGW · Insider Trading
Bone Biologics Corp Warrants
Every open-market purchase and sale reported by BBLGW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-21 | Jeff Frelick | Chief Executive Officer | A | — | — |
| 2026-01-21 | Deina H Walsh | Chief Financial Officer | A | — | — |
| 2025-06-06 | Robert E. Gagnon | Director | A | +62,894 deriv. | — |
| 2025-06-06 | Phillip Terry Meikle II | Director | A | +62,894 deriv. | — |
| 2025-06-06 | Siddhesh Rajendra Angle | Director | A | +62,894 deriv. | — |
| 2025-06-06 | Bruce Stroever | Director | A | +62,894 deriv. | — |
| 2025-01-21 | Jeff Frelick | Chief Executive Officer | A | — | — |
| 2025-01-21 | Deina H Walsh | Chief Financial Officer | A | — | — |
| 2024-10-18 | Phillip Terry Meikle II | Director | A | +28,194 deriv. | — |
| 2024-09-19 | Siddhesh Rajendra Angle | Director | A | +30,713 deriv. | — |
| 2024-09-19 | Robert E. Gagnon | Director | A | +30,713 deriv. | — |
| 2024-09-19 | Bruce Stroever | Director | A | +30,713 deriv. | — |
| 2024-01-19 | Deina H Walsh | Chief Financial Officer | A | — | — |
| 2024-01-19 | Jeff Frelick | Chief Executive Officer | A | — | — |
| 2024-01-10 | Robert E. Gagnon | Director | A | +17 deriv. | — |
| 2023-09-20 | Siddhesh Rajendra Angle | Director | A | +85,763 deriv. | — |
| 2023-09-20 | Erick Lucera | Director | A | +85,763 deriv. | — |
| 2023-09-20 | Bruce Stroever | Director | A | +85,763 deriv. | — |
| 2023-09-14 | Deina H Walsh | Chief Financial Officer | Buy | +8,000 | +$5.12K |
| 2023-09-12 | Jeff Frelick | Chief Executive Officer | Buy | +9,500 | +$6.53K |
| 2023-09-07 | Deina H Walsh | Chief Financial Officer | Buy | +7,000 | +$4.97K |
| 2023-09-05 | Jeff Frelick | Chief Executive Officer | Buy | +7,600 | +$5.02K |
| 2023-03-29 | Don Hankey | Chairman of the Board | J | −1,000,274 | — |
| 2023-03-08 | Erick Lucera | Director | A | +36,845 deriv. | — |
| 2023-03-08 | Jeff Frelick | Chief Executive Officer | A | +37,750 deriv. | — |
| 2023-03-08 | Deina H Walsh | Chief Financial Officer | A | +18,875 deriv. | — |
| 2023-03-08 | Bruce Stroever | Director | A | +36,845 deriv. | — |
| 2023-03-08 | Siddhesh Rajendra Angle | Director | A | +36,845 deriv. | — |
| 2022-02-28 | Bruce Stroever | Director | A | +11,671 deriv. | — |
| 2022-02-28 | Erick Lucera | Director | A | +11,671 deriv. | — |
| 2022-02-28 | Deina H Walsh | Chief Financial Officer | A | +25,000 deriv. | — |
| 2022-02-28 | Siddhesh Rajendra Angle | Director | A | +11,671 deriv. | — |
| 2022-02-28 | Jeff Frelick | Chief Executive Officer | A | +50,000 deriv. | — |
| 2021-10-19 | Don Hankey | Chairman of the Board | MIXED | −7,922,096 | +$34.63M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jeff Frelick | Chief Executive Officer | 360 | $2.77K |
| Deina H Walsh | Chief Financial Officer | 313 | $2.41K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BBLGW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.